Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder CancerZacks Investment Research • 09/21/26
Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock?The Motley Fool • 09/20/26
Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive.The Motley Fool • 09/17/26
How a Roth IRA Can Keep Thousands More of Your High-Yield Dividend Income Compounding24/7 Wall Street • 09/16/26
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferenceBusiness Wire • 09/15/26
Pfizer Inc. (PFE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center StageMarketBeat • 09/14/26
Here are the stocks to favor in the fourth quarter — and those you should avoidMarket Watch • 09/10/26
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?Zacks Investment Research • 09/09/26